IGF-1 LR3

Researchers investigate IGF-1 LR3 peptide within controlled laboratory environments to examine modified peptide structures and molecular mechanisms. Experimental cell culture models utilize this compound to study peptide analog characteristics in vitro. Controlled laboratory peptide stability studies assess compound properties under standardized experimental conditions. Scientists explore structural modifications and binding protein interactions in research settings. Laboratory personnel examine modified peptide behavior in experimental models designed for growth factor analog research. These investigations occur exclusively in controlled research environments without clinical applications.

IGF-1 LR3 is investigated in research environments to understand modified growth factor peptide mechanisms. This compound is studied within controlled laboratory models examining peptide analog properties. Researchers explore this peptide for experimental peptide research applications in academic and institutional settings. Laboratory studies examine the compound’s structural characteristics under standardized protocols. Scientists investigate molecular properties relevant to growth factor analog research methodologies. All research applications remain confined to laboratory environments and experimental frameworks.

Store IGF-1 LR3 peptide at -20°C for optimal long-term stability before reconstitution. Storage temperature should remain consistent to maintain compound integrity. Keep the product sealed until ready for laboratory use. Laboratory handling should occur only by qualified research personnel trained in peptide research protocols. Avoid exposure to moisture, heat, and direct sunlight during storage. Use appropriate laboratory equipment when handling this research compound. Reconstitution should follow standard laboratory peptide preparation procedures using sterile techniques. After reconstitution, store at 2-8°C according to institutional protocols. Maintain proper documentation of handling and storage conditions for research records. Dispose of unused material according to institutional laboratory waste protocols.

Each batch undergoes comprehensive purity verification procedures to confirm research-grade quality. Third-party testing validates compound purity at 99%+ by LC-MS analysis. Batch-to-batch consistency ensures reliable results across research protocols. Certificate of Analysis accompanies each order documenting purity verification results. Internal quality assurance standards maintain strict compound specifications. Testing procedures verify molecular weight, purity percentage, structural modifications, and compound identity. Research-grade supply positioning ensures suitability for controlled laboratory investigations. Quality control documentation supports institutional research compliance requirements.

• CAS: 946870-92-4
• Chemical Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
• Molecular Weight: 9117.60 g/mol
• Peptide Sequence: MFPAMPLSSL–FVNGPRTLCG–AYGGSCASFR–RGFYFNKPTG–YGSSTKKAYG–NNYRRHPLLK–PPIKSAQG
• Synonyms: Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i, IGF-I analog
• Shelf life: 24 months from the manufacturing date.

IGF-1 LR3 is a synthetic modified peptide analog compound produced for research applications. This peptide is a modified version of insulin-like growth factor with structural alterations. The modification includes additional amino acids creating an extended peptide chain. The “Long R3” designation refers to the specific structural modification present. Modified peptides are studied to understand how structural changes affect molecular properties. This analog demonstrates altered binding characteristics with binding proteins in experimental systems. This synthetic peptide origin ensures batch-to-batch consistency for research protocols. The compound consists of a defined amino acid sequence with specific modifications. Researchers examine this modified peptide’s properties within controlled laboratory conditions without therapeutic context.

This synthetic research peptide formulation provides laboratories with a modified insulin-like growth factor compound for experimental studies. The compact 1mg format supports controlled research applications in qualified laboratory settings. Each batch undergoes rigorous purity verification to ensure consistency across research protocols. High-purity formulation meets research-grade standards for modified growth factor investigations. Secure packaging protects compound integrity during storage and transport. Discreet shipment ensures confidential delivery to research facilities and institutional laboratories.